La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Guerbet Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

David Hale

Amministratore delegato

€1.5m

Compenso totale

Percentuale dello stipendio del CEO	31.7%
Mandato del CEO	4.6yrs
Proprietà del CEO	n/a
Durata media del management	4.6yrs
Durata media del Consiglio di amministrazione	7.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Guerbet (EPA:GBT) Using Too Much Debt?

Apr 27

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Feb 29

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Mar 28

Is Guerbet (EPA:GBT) A Risky Investment?

Oct 25

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Sep 23

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

May 27

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

May 04

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Apr 05

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 19

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

Mar 01

When Should You Buy Guerbet SA (EPA:GBT)?

Feb 10

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 28

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Jan 13

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

Dec 23

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Dec 11

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Nov 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Hale rispetto agli utili di Guerbet?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	€1m	€470k	€24m
Sep 30 2023	n/a	n/a	-€9m
Jun 30 2023	n/a	n/a	-€42m
Mar 31 2023	n/a	n/a	-€42m
Dec 31 2022	€1m	€470k	-€41m
Sep 30 2022	n/a	n/a	-€14m
Jun 30 2022	n/a	n/a	€13m
Mar 31 2022	n/a	n/a	€23m
Dec 31 2021	€2m	€470k	€33m
Sep 30 2021	n/a	n/a	€33m
Jun 30 2021	n/a	n/a	€33m
Mar 31 2021	n/a	n/a	€26m
Dec 31 2020	€933k	€470k	€18m

Compensazione vs Mercato: La retribuzione totale di David ($USD 1.64M ) è superiore alla media delle aziende di dimensioni simili nel mercato French ($USD 551.56K ).

Compensazione vs guadagni: La retribuzione di David è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

David Hale (56 yo)

4.6yrs

Mandato

€1,481,777

Compensazione

Mr. David Hale served as Independent Director of Orpea SA since July 28, 2022 until January 2024. He has been Chief Executive Officer of Guerbet SA since January 1, 2020 and serves as its MD & GM. Mr. Hale...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hale	CEO, MD & GM	4.6yrs	€1.48m	Nessun dato
Philippe Bourrinet	Chief Pharmacist	4.6yrs	€11.50k	Nessun dato
Jerome Estampes	CFO and Senior VP of Business Development & Licensing	5.3yrs	Nessun dato	Nessun dato
Sarah Dayre	Senior VP of Technical Operations & Interim Chief Pharmacist	3.5yrs	Nessun dato	Nessun dato
Charlotte Bamiere	Director of Legal Affairs	8.6yrs	Nessun dato	Nessun dato
Christine Allard	Senior Vice President of Public Affairs & Corporate Communications	no data	Nessun dato	Nessun dato
Eva Ohlsson	Senior Vice President of Human Resources	no data	Nessun dato	Nessun dato
Jean-Francois Blanc	Senior Vice President of Interventional Imaging	3.6yrs	Nessun dato	Nessun dato
Francois Nicolas	Senior VP of R&D	6.9yrs	Nessun dato	Nessun dato
Valérie Brissart	Senior Vice President of Diagnostic Imaging	4.6yrs	Nessun dato	Nessun dato
Mathieu Elie	Senior Vice President of Commercial Operations - Asia-Pacific	4.6yrs	Nessun dato	Nessun dato
Gitte Hesselholt	Senior Vice President of Commercial Operations - Americas & EMEA	4.6yrs	Nessun dato	Nessun dato

4.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di GBT è considerato esperto (durata media dell'incarico 4.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michel Guerbet	Honorary Chairman	no data	€18.96k	55.13% € 233.0m
Hugues Lecat	Chairman of the Board	less than a year	Nessun dato	Nessun dato
Claire Jouault-Massiot	Non-Independent Director	11.3yrs	€27.60k	Nessun dato
Mark Fouquet	Non-Independent Director	10.3yrs	€27.60k	Nessun dato
Didier Izabel	Independent Director	10.3yrs	€109.68k	Nessun dato
Céline Lamort	Non-Independent Director	9.3yrs	€27.60k	Nessun dato
Nicolas Louvet	Non-Independent Director	8.3yrs	€26.40k	Nessun dato
Eric Guerbet	Non-Independent Director	7.3yrs	€27.60k	Nessun dato
Jean-Sebastien Raynaud	Employee Director	3.8yrs	Nessun dato	Nessun dato
Olivier Fougère	Employee Director	3.4yrs	Nessun dato	Nessun dato
Marc Massiot	Non-Independent Director	3.3yrs	€20.40k	Nessun dato
Carine Dagommer	Non-Independent Director	2.3yrs	€25.20k	Nessun dato

7.3yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GBT sono considerati esperti (durata media dell'incarico 7.3 anni).

Guerbet Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Guerbet SA Announces Board Changes

Guerbet SA, Annual General Meeting, May 24, 2024

Guerbet Announces Management Appointments

Guerbet SA, Annual General Meeting, May 26, 2023

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet SA, Annual General Meeting, May 28, 2021

Recent updates

Guerbet SA Announces Board Changes

Is Guerbet (EPA:GBT) Using Too Much Debt?

Guerbet SA Provides Earnings Guidance for the Year 2024

Dividend of €0.50 announced

Price target increased by 22% to €36.38

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

New minor risk - Share price stability

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Price target increased by 8.4% to €20.68

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

Price target decreased to €23.94

Consensus forecasts updated

Price target decreased to €26.82

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Price target decreased to €30.90

Consensus forecasts updated

Price target decreased to €32.80

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Price target decreased to €31.55

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Price target decreased to €36.18

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings: Revenues in line with analyst expectations

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Price target increased to €33.75

Consensus forecasts updated

Upcoming dividend of €0.70 per share

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Full year 2020 earnings released

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

New 90-day low: €29.85

Analysts update estimates

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.65

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

New 90-day high: €33.10

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

New 90-day high: €30.00

Analysts lower EPS estimates to €1.64

Price target lowered to €31.00

First half earnings released

Analysts lower EPS estimates to €1.98